Nick Abbott
Stock Analyst at Wells Fargo
(0.06)
# 3,312
Out of 4,415 analysts
7
Total ratings
20%
Success rate
-36.09%
Average return
Main Sectors:
Top Industries:
6 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZYME Zymeworks | Assumes: Overweight | $45 → $9 | $9.00 | - | 1 | Oct 4, 2022 | |
| TCRT Alaunos Therapeutics | Assumes: Overweight | $45 | $1.36 | +3,208.82% | 2 | Oct 4, 2022 | |
| ADAP Adaptimmune Therapeutics | Maintains: Equal-Weight | $7 → $1.5 | $1.19 | +26.05% | 1 | Oct 4, 2022 | |
| CALA Calithera Biosciences | Maintains: Equal-Weight | $60 → $40 | $0.02 | +199,900.00% | 1 | May 11, 2022 | |
| CLLS Cellectis | Downgrades: Equal-Weight | $16 | $2.99 | +435.12% | 1 | Jan 6, 2022 | |
| AFMD Affimed | Maintains: Overweight | $100 → $150 | $5.30 | +2,730.19% | 1 | Mar 24, 2021 |
Zymeworks
Oct 4, 2022
Assumes: Overweight
Price Target: $45 → $9
Current: $9.00
Upside: -
Alaunos Therapeutics
Oct 4, 2022
Assumes: Overweight
Price Target: $45
Current: $1.36
Upside: +3,208.82%
Adaptimmune Therapeutics
Oct 4, 2022
Maintains: Equal-Weight
Price Target: $7 → $1.5
Current: $1.19
Upside: +26.05%
Calithera Biosciences
May 11, 2022
Maintains: Equal-Weight
Price Target: $60 → $40
Current: $0.02
Upside: +199,900.00%
Cellectis
Jan 6, 2022
Downgrades: Equal-Weight
Price Target: $16
Current: $2.99
Upside: +435.12%
Affimed
Mar 24, 2021
Maintains: Overweight
Price Target: $100 → $150
Current: $5.30
Upside: +2,730.19%